Literature DB >> 20621370

Impact of left atrial volume in prediction of outcome after cardiac resynchronization therapy.

Xuedong Shen1, Chandra K Nair, Mark J Holmberg, Aryan N Mooss, Jacob Koruth, Fenwei Wang, Stephanie Maciejewski, Dennis J Esterbrooks.   

Abstract

UNLABELLED: Left atrial volume index (LAVI) as a predictor of mortality has not been well investigated in patients with cardiac resynchronization therapy (CRT). The purpose of this study is to evaluate the impact of LAVI in predicting mortality in CRT patients.
METHODS: We studied 100 consecutive patients who received CRT (male 73, age 69.9 ± 9.6 years). The follow-up duration of all echocardiographic measurements was 14.4 ± 10.5 months after CRT. LAVI was measured from apical views on two-dimensional echocardiography by bi-plane rule. A decrease of left ventricular end systolic volume ≥ 15% after CRT was defined as a positive response to CRT.
RESULTS: The mean LAVI at baseline was 59.9 ± 22.7 ml/m(2). LAVI in patients who died (78.2 ± 27.5 ml/m(2)) was significantly greater than those who survived (55.9 ± 19.5 ml/m(2), p<0.0001) during follow-up of 17 ± 10.6 months. The area under ROC curve (AUC) for LAVI predicting death was 0.77 (p=0.0001). The cutoff point for LAVI predicting death was LAVI>59.4 ml/m(2). LAVI>59.4 ml/m(2) was related to mortality by Cox proportional univariate regression [hazard ratio (HR)=5.15, 95% CI=1.48-17.93, p=0.01]. After adjustment for the variables with significant difference by univariate regression, LAVI>59.4 ml/m(2) was continuously related to mortality by multivariate regression (HR=4.56, 95% CI, 1.30-15.97, p=0.02). LAVI>59.4 ml/m(2) was associated with a near 5-fold increase in mortality during follow-up of 17 ± 10.6 months.
CONCLUSION: Patients who have LAVI>59.4 ml/m(2) continue to have increased mortality despite CRT.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20621370     DOI: 10.1016/j.ijcard.2010.06.016

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events.

Authors:  Naomi D Herz; Joseph Engeda; Robbert Zusterzeel; William E Sanders; Kathryn M O'Callaghan; David G Strauss; Samantha B Jacobs; Kimberly A Selzman; Ileana L Piña; Daniel A Caños
Journal:  J Womens Health (Larchmt)       Date:  2015-03-20       Impact factor: 2.681

3.  Left atrial size and function as assessed by computed tomography in cardiac resynchronization therapy: Association to echocardiographic and clinical outcome.

Authors:  Peter Bomholt Hansen; Anders Sommer; Bjarne Linde Nørgaard; Mads Brix Kronborg; Jens Cosedis Nielsen
Journal:  Int J Cardiovasc Imaging       Date:  2017-01-25       Impact factor: 2.357

4.  Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib.

Authors:  Y Wang; D Tang; A Sui; W Jiao; Y Luo; M Wang; R Yang; Z Wang; Y Shen
Journal:  Clin Transl Oncol       Date:  2012-10-11       Impact factor: 3.405

5.  Combined management of atrial fibrillation and heart failure: case studies.

Authors:  Frederik H Verbrugge; Wilfried Mullens
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

6.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.